AntibodystaleBristol Myers SquibbPhase 2
nivolumab (Opdivo, Nivolumab Infusion [Opdivo])
Intermediate Risk Prostate Cancer; Castration-resistant Prostate Cancer · Intermediate Risk Prostate Cancer
#IntermediateRiskProstateCancer#Antibody#Phase2#항체#면역항체+3
효능 ORR 5%임상시험 1상태 DISCONTINUED